Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.

Dean Y, D├ępis F, Kosco-Vilbois M.

Swiss Med Wkly. 2012 Nov 28;142:w13711. doi: 10.4414/smw.2012.13711. Review.

2.

Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.

Kuhn C, Weiner HL.

Immunotherapy. 2016 Jul;8(8):889-906. doi: 10.2217/imt-2016-0049. Epub 2016 May 10. Review.

3.

CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.

Chatenoud L, Waldmann H.

Rev Diabet Stud. 2012 Winter;9(4):372-81. doi: 10.1900/RDS.2012.9.372. Epub 2012 Dec 28. Review.

4.

Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.

Bisikirska BC, Herold KC.

Ann N Y Acad Sci. 2004 Dec;1037:1-9. Review.

PMID:
15699486
5.

Anti-CD3 clinical trials in type 1 diabetes mellitus.

Daifotis AG, Koenig S, Chatenoud L, Herold KC.

Clin Immunol. 2013 Dec;149(3):268-78. doi: 10.1016/j.clim.2013.05.001. Epub 2013 May 11. Review.

PMID:
23726024
6.

CD3 antibody treatment stimulates the functional capability of regulatory T cells.

Chatenoud L.

Novartis Found Symp. 2003;252:279-86; discussion 286-90. Review.

PMID:
14609225
7.

Anti-CD3 mAbs for treatment of type 1 diabetes.

Kaufman A, Herold KC.

Diabetes Metab Res Rev. 2009 May;25(4):302-6. doi: 10.1002/dmrr.933. Review.

PMID:
19319985
8.

Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity.

Chatenoud L.

Curr Opin Organ Transplant. 2009 Aug;14(4):351-6. Review.

PMID:
19610168
9.

T cell immunomodulation--the Holy Grail of therapeutic tolerance.

Isaacs JD.

Curr Opin Pharmacol. 2007 Aug;7(4):418-25. Epub 2007 Jul 3. Review.

PMID:
17611158
10.

Teplizumab for treatment of type 1 diabetes mellitus.

Skelley JW, Elmore LK, Kyle JA.

Ann Pharmacother. 2012 Oct;46(10):1405-12. doi: 10.1345/aph.1R065. Epub 2012 Sep 11. Review.

PMID:
22968521
11.

Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.

Miller SA, St Onge E.

Expert Opin Biol Ther. 2011 Nov;11(11):1525-32. doi: 10.1517/14712598.2011.610789. Epub 2011 Sep 14. Review.

PMID:
21913874
12.

CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.

Chatenoud L.

Curr Opin Immunol. 2005 Dec;17(6):632-7. Epub 2005 Oct 7. Review.

PMID:
16214320
13.

Induction of immunological tolerance by oral anti-CD3.

da Cunha AP, Weiner HL.

Clin Dev Immunol. 2012;2012:425021. doi: 10.1155/2012/425021. Epub 2011 Nov 14. Review.

14.
15.

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.

Shepherd J, Rogers G, Anderson R, Main C, Thompson-Coon J, Hartwell D, Liu Z, Loveman E, Green C, Pitt M, Stein K, Harris P, Frampton GK, Smith M, Takeda A, Price A, Welch K, Somerville M.

Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. Review.

16.

CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic.

Chatenoud L.

Int Rev Immunol. 2006 May-Aug;25(3-4):215-33. Review.

PMID:
16818372
17.

CD3-specific antibodies: a portal to the treatment of autoimmunity.

Chatenoud L, Bluestone JA.

Nat Rev Immunol. 2007 Aug;7(8):622-32. Epub 2007 Jul 20. Review.

PMID:
17641665
18.
19.
20.

Immunosuppressive therapy of autoimmune diseases.

Bach JF.

Immunol Today. 1993 Jun;14(6):322-6. Review. Erratum in: Immunol Today. 2008 Apr;29(4):149.

PMID:
8104411

Supplemental Content

Support Center